Geron Co. (NASDAQ:GERN) gapped up before the market opened on Tuesday . The stock had previously closed at $5.45, but opened at $5.73. Geron shares last traded at $5.96, with a volume of 12126355 shares trading hands.

GERN has been the subject of a number of recent research reports. ValuEngine raised shares of Geron from a “hold” rating to a “buy” rating in a research report on Wednesday, May 23rd. B. Riley assumed coverage on shares of Geron in a research note on Thursday, July 5th. They set a “buy” rating and a $5.75 target price on the stock. BidaskClub cut shares of Geron from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Finally, FBR & Co assumed coverage on shares of Geron in a research note on Thursday, July 5th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $5.31.

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -33.44 and a beta of 3.11.

Geron (NASDAQ:GERN) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). Geron had a negative net margin of 3,232.73% and a negative return on equity of 23.15%. The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. equities research analysts forecast that Geron Co. will post 0.39 earnings per share for the current year.

In related news, EVP Stephen Rosenfield sold 1,362,250 shares of Geron stock in a transaction on Friday, August 24th. The shares were sold at an average price of $4.51, for a total transaction of $6,143,747.50. Following the transaction, the executive vice president now owns 36,000 shares in the company, valued at approximately $162,360. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 8.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale purchased a new position in shares of Geron during the 1st quarter valued at $106,000. Element Capital Management LLC purchased a new stake in Geron in the 1st quarter worth $227,000. SG Americas Securities LLC lifted its stake in Geron by 352.2% in the 2nd quarter. SG Americas Securities LLC now owns 57,936 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 45,124 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Geron in the 1st quarter worth $250,000. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in Geron by 57.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 70,970 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 25,900 shares in the last quarter. Institutional investors own 37.17% of the company’s stock.

Geron Company Profile (NASDAQ:GERN)

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

See Also: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.